{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:33:14Z","timestamp":1740130394449,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12017X04"],"award-info":[{"award-number":["SHDC12017X04"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of delivering radiotherapy for pancreatic ductal adenocarcinoma patients was to sterilize vessel margin, increase R0 resection rate and delay local progression. Whether preoperative radiotherapy could prolong overall survival of surgical candidates remained unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma patients receiving radical resection from surveillance, epidemiology and end result database were enrolled. Propensity score matching was conducted to balance difference in baseline characteristics, and survival analyses were performed to compare overall survival between preoperative radiotherapy and upfront resection groups. Cox proportional hazard regression model and subgroup analyses were utilized to identify prognostic factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 11\u00a0665 and 597 pancreatic ductal adenocarcinoma patients receiving upfront resection and preoperative radiotherapy followed by resection from 2004 to 2016 were identified, respectively, while baseline characteristics were distinct between groups. After propensity score matching, preoperative radiotherapy was not associated with better overall survival (upfront resection vs preoperative radiotherapy, 26 vs 27\u00a0months). Subgroup analyses showed that preoperative radiotherapy was a protective factor in pT4 (hazard ratio\u00a0=\u00a00.64, 95% confidence interval: 0.47\u20130.88) but a negative predictor in pT1 (hazard ratio\u00a0=\u00a01.79, 95% confidence interval: 1.08\u20132.97) patient populations. Survival analyses showed that preoperative radiotherapy improved overall survival of patients with pT4 stage (upfront resection vs preoperative radiotherapy, 19 vs 25\u00a0months) and involvement of celiac axis, superior mesenteric artery and aorta (upfront resection vs preoperative radiotherapy, 20 vs 27\u00a0months), while preoperative radiotherapy was associated with worse overall survival in patients with pT1 tumor (upfront resection vs preoperative radiotherapy, 39 vs 24\u00a0months).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Preoperative radiotherapy could improve survival of resected pancreatic ductal adenocarcinoma patients with pT4 stage or with celiac axis, superior mesenteric artery and aorta invasion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa035","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T20:20:13Z","timestamp":1583266813000},"page":"679-687","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-518X","authenticated-orcid":false,"given":"Yaolin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zizhen","family":"Wu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dansong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchuan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantao","family":"Kuang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Lou","sequence":"first","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"2020061005544311300_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2020061005544311300_ref2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","article-title":"A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study Group of Adjuvant Therapy for pancreatic cancer","volume":"101","author":"Ueno","year":"2009","journal-title":"Br J Cancer"},{"key":"2020061005544311300_ref3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"2020061005544311300_ref4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/SLA.0b013e3181613142","article-title":"Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?","volume":"247","author":"Schnelldorfer","year":"2008","journal-title":"Ann Surg"},{"volume-title":"Pancreatic Adenocarcinoma, NCCN Clinical Practice Guidelines in Oncology, Version 3.2019 edition","year":"2019","author":"Tempero","key":"2020061005544311300_ref5"},{"key":"2020061005544311300_ref6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"2020061005544311300_ref7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jso.23921","article-title":"Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability","volume":"111","author":"Nanda","year":"2015","journal-title":"J Surg Oncol"},{"key":"2020061005544311300_ref8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1245\/s10434-010-1456-7","article-title":"Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer","volume":"18","author":"Stokes","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2020061005544311300_ref9","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1245\/s10434-010-1019-y","article-title":"Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration","volume":"17","author":"Polistina","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2020061005544311300_ref10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"2020061005544311300_ref11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1245\/ASO.2005.04.503","article-title":"Docetaxel\/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma","volume":"12","author":"Pipas","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2020061005544311300_ref12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2004.03.026","article-title":"Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer","volume":"60","author":"Joensuu","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020061005544311300_ref13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00000421-200302000-00007","article-title":"Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer","volume":"26","author":"Aristu","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"2020061005544311300_ref14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1097-0142(20000715)89:2<314::AID-CNCR16>3.0.CO;2-V","article-title":"Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial","volume":"89","author":"Snady","year":"2000","journal-title":"Cancer"},{"volume-title":"WHO Classification of Tumours of the Digestive System: [Reflects the Views of a Working Group that Convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, December 10\u201312, 2009]","year":"2010","author":"World","key":"2020061005544311300_ref15"},{"key":"2020061005544311300_ref16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JCO.1997.15.3.928","article-title":"Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"15","author":"Spitz","year":"1997","journal-title":"J Clin Oncol"},{"key":"2020061005544311300_ref17","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1200\/JCO.1998.16.12.3843","article-title":"Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma","volume":"16","author":"Pisters","year":"1998","journal-title":"J Clin Oncol"},{"key":"2020061005544311300_ref18","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020061005544311300_ref19","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.2002.11.064","article-title":"Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome","volume":"20","author":"Pisters","year":"2002","journal-title":"J Clin Oncol"},{"key":"2020061005544311300_ref20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(95)02134-5","article-title":"Radiosensitization of pancreatic cancer cells by 2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine","volume":"34","author":"Lawrence","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020061005544311300_ref21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"2020061005544311300_ref22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-8-148","article-title":"SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience","volume":"8","author":"Tozzi","year":"2013","journal-title":"Radiat Oncol"},{"key":"2020061005544311300_ref23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jss.2011.07.044","article-title":"Stereotactic body radiation therapy for nonresectable tumors of the pancreas","volume":"174","author":"Goyal","year":"2012","journal-title":"J Surg Res"},{"key":"2020061005544311300_ref24","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","article-title":"Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020061005544311300_ref25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"key":"2020061005544311300_ref26","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/6\/679\/33374252\/hyaa035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/6\/679\/33374252\/hyaa035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T09:55:02Z","timestamp":1591782902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/6\/679\/5830796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,6]]},"published-print":{"date-parts":[[2020,6,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa035","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,5,6]]}}}